Abbott to Showcase Innovations to Help Labs Solve Health Care Challenges at the American Association for Clinical Chemistry Lab Expo

"Abbott is designing the next generation of diagnostics solutions to help health care providers achieve faster and more accurate test results," said Brian Blaser, executive vice president, Diagnostics Products, Abbott. "Abbott is focused on providing an integrated diagnostic solution, powered by innovations that can help our customers channel change into growth and ensure exceptional performance."

During the AACC meeting, Abbott will feature a variety of innovations focused on increased testing volumes and improving efficiencies:

• Core Laboratory: Abbott recently launched a next generation automation solution, the ACCELERATOR a3600, which doubles per-hour processing capacity compared to previous systems. By partnering with Abbott, studies have shown a core lab can eliminate a significant percentage of associated operating costs through automation and standardization of testing.

• Molecular: Abbott's m2000 RealTime System for automated infectious disease molecular testing gives labs the ability to handle greater volumes at reduced costs on a single platform. Labs that use Abbott's molecular automated solutions may process the same number of tests with fewer instruments.

• Point of Care: Used at a patient's bedside, the i-STAT System allows physicians and nurses to quickly and accurately analyze lab-quality results within minutes, rather than hours, to accelerate decision-making and ensure patients receive the most effective and efficient care.

• Informatics: Abbott provides laboratories with a powerful suite of informatics solutions to manage large volumes of data across health care systems, helping labs simplify complex processes to make information actionable. Leading hospitals, reference labs, and blood banks use Abbott's informatics technology to help treat and monitor various diseases and medical conditions.

• Bio-Identification: When a patient is admitted to the hospital with a suspected infection, clinicians try to determine the cause using testing technology that may take days to weeks, potentially leading to significant delays in appropriate treatment. Abbott's IRIDICA platform, currently under development and targeted for release in CE-marked European countries within 12 months, has the potential to change the way doctors diagnose serious infections.

Scientific Presentations and Posters During the AACC program, Abbott will present more than 40 scientific presentations and/or posters related to the company's solutions. A complete list of Abbott's presentations, posters and workshops can be found at www.abbottdiagnostics.com.

About Abbott Diagnostics Abbott is a global leader in in vitro diagnostics offering a broad portfolio spanning immunoassay, clinical chemistry, hematology, blood screening, molecular, bio-identification, point of care, and informatics. Our diagnostics solutions are more than just a test or data point – working together across our business units and more than 22,000 customers in more than 100 countries – they are designed to anticipate, leverage and improve decision-making and patient care across the entire health care system. As one of the only diagnostics business serving such a broad portfolio, Abbott is focused on an integrated diagnostics solution—powered by innovations that can help our customers channel change into growth and ensure exceptional performance.

About AbbottAbbott is a global health care company devoted to improving life through the development of products and technologies that span the breadth of health care. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 69,000 people.

Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.